Thus, maintaining the expression levels of StarD5 may represent a possible therapeutic target for NASH and MAFLD, given its role in lipid homeostasis and fibrosis; its downregulation or ablation has been shown to accelerate the progression of steatosis and liver fibrosis [18]. Here, STARD5 is linked to metabolic dysfunction-associated steatohepatitis.